EA
ACAD icon

Evolution Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Evolution Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+10
New +$220 ﹤0.01% 209

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Evolution Advisers's ACAD Position: Q2 2026 in Review

Evolution Advisers opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 10 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #209 among its holdings.

352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Evolution Advisers held 10 shares of Acadia Pharmaceuticals worth $0 as of Q2 2026.
  • Acadia Pharmaceuticals was a new Evolution Advisers position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #209 holding.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.